MedPath
Found 10 clinical trials|View Analysis
Sort by:

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Phase 2
Recruiting
Conditions
Hematologic Malignancy
Graft Versus Host Disease
Interventions
Drug: Methotrexate
Drug: Post-Transplant Cyclophosphamide
Drug: Fludarabine
Drug: Cycophosphamide
Drug: Anti-Thymoglobulin
Other: Donor Lymphocytes Injection
Radiation: total body irradiation
Other: hematopoietic stem cells
Drug: Thiotepa
Other: Graft nuclear cells
Drug: Busulfan
Drug: Clofarabine
First Posted Date
2024-02-12
Last Posted Date
2024-10-28
Lead Sponsor
Nantes University Hospital
Target Recruit Count
82
Registration Number
NCT06252870
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

CHU Brest, Brest, France

🇫🇷

CHU Nantes, Nantes, France

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Phase 1
Recruiting
Conditions
Fanconi Anemia
Interventions
Drug: JSP191
Device: CliniMACS Prodigy System
Biological: Depleted Stem Cell Transplant
Biological: Rabbit Anti-Thymoglobulin (rATG)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
First Posted Date
2021-03-05
Last Posted Date
2023-12-14
Lead Sponsor
Porteus, Matthew, MD
Target Recruit Count
12
Registration Number
NCT04784052
Locations
🇺🇸

Stanford University, Stanford, California, United States

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

First Posted Date
2021-02-26
Last Posted Date
2023-12-05
Lead Sponsor
University of Southern California
Target Recruit Count
80
Registration Number
NCT04773392
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

Phase 4
Conditions
Lymphoblastic Lymphoma
Interventions
First Posted Date
2016-10-19
Last Posted Date
2016-10-25
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
130
Registration Number
NCT02938741
Locations
🇨🇳

Shanghai First People's HOSPITAL, Shanghai, China

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Phase 4
Completed
Conditions
Leukemia, GVHD, ATG, Transplantation
Interventions
First Posted Date
2013-05-17
Last Posted Date
2020-09-25
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
300
Registration Number
NCT01856803
Locations
🇨🇳

Peking university people's hospital, Beijing, Beijing, China

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Phase 4
Withdrawn
Conditions
Kidney Transplantation
Renal Transplantation
Reperfusion Injury
Interventions
First Posted Date
2010-06-24
Last Posted Date
2014-06-09
Lead Sponsor
Georgetown University
Registration Number
NCT01149993

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Phase 2
Completed
Conditions
Acute Renal Allograft Rejection
Cadaveric Donor Renal Transplantation
Induction Therapy
Interventions
Drug: Simulect (basliximab)
Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
First Posted Date
2005-10-10
Last Posted Date
2015-03-18
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
240
Registration Number
NCT00235300
Locations
🇺🇸

UCLA School of Medicine, Los Angeles, California, United States

🇺🇸

Florida Hospital Medical Center and Translife, Orlando, Florida, United States

🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

and more 25 locations

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2
Completed
Conditions
Leukemia, Mast-Cell
Mantle-cell Lymphoma
Interventions
First Posted Date
2005-09-16
Last Posted Date
2017-11-28
Lead Sponsor
Stanford University
Target Recruit Count
36
Registration Number
NCT00186628
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Phase 2
Completed
Conditions
Renal Transplantation
Graft Rejection
First Posted Date
2004-08-20
Last Posted Date
2015-03-18
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
150
Registration Number
NCT00089947
Locations
🇺🇸

Keck USC School of Medicine, Los Angeles, California, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

and more 16 locations

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

Not Applicable
Completed
Conditions
Acute Myelogenous Leukemia (AML)
Graft vs. Host Disease (GvHD)
Acute Lymphocytic Leukemia (ALL)
Interventions
Biological: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
First Posted Date
2004-07-30
Last Posted Date
2015-03-18
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
60
Registration Number
NCT00088543
Locations
🇺🇸

Beth Israel Deaconess Medical Center KS121, Brookline, Massachusetts, United States

🇨🇦

Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

🇺🇸

Shands at the University of Florida, Division of Hematology/Oncology, Gainesville, Florida, United States

and more 11 locations
© Copyright 2025. All Rights Reserved by MedPath